Kusuri-sodan — OTC Safety Companion for Japan
A Japanese-language app that screens you for the right OTC medication when no pharmacist is on the floor, flags interactions with your existing prescriptions and conditions, and produces a printable 'I checked this is safe for me' note to bring back to your doctor.
Japanese adults self-medicating for headaches, menstrual pain, colds, or stomach issues who increasingly buy OTC drugs without pharmacist guidance
- Symptom-to-ingredient matcher covering the OTC catalog (ロキソニンS, ガスター10, トランシーノEX etc.) with risk-class awareness under the new 指定第2類 rules
- Personal medication and condition profile that screens for ingredient conflicts, age warnings, and pregnancy flags
- Photo-scan of any drug package to pull dosing, contraindications, and a one-tap 'register I took this' log
- Family mode that keeps separate profiles for kids and elderly relatives shopping at the same drugstore
Japan's health ministry just approved pharmacist-free sales of loxoprofen and is reviewing more ingredients, so consumers will increasingly self-select OTC drugs with less professional guidance — and need a private safety net.
Government is actively expanding pharmacist-free OTC sales (loxoprofen approved July 2026, more ingredients under review), and PMC research confirms Japanese self-medication has grown since 2009 with consumers paying little attention to package risks — a real safety gap to fill.Analysis of Japanese consumers' attitudes toward the digital transformation of OTC medicine purchase behavior and eHealth literacy ↗薬剤師いなくてもロキソニン購入可に 厚労省調査会が条件付きで了承 ↗
Existing tools are pharmacist-facing or academic (Kegg Medicus, yusuketakuma pharmacist tools, wia.tools, PillFYI) — no consumer Japanese-language app that takes symptoms as input, screens OTC candidates, and outputs an interaction-checked printable note. Adjacent 電子お薬手帳 apps track prescriptions but don't screen OTC selections.Kegg Medicus 医薬品相互作用チェック ↗併用禁忌・相互作用チェッカー | 薬剤師のための無料ツール ↗【2026年最新】おすすめお薬手帳アプリ7選 ↗
Japanese app users have notoriously low willingness to pay and the dominant 電子お薬手帳 category is free; no consumer-priced OTC interaction app exists to benchmark WTP. B2C subscription is plausible but unproven — would likely need B2B2C via drugstores or insurance tie-in.【2026年最新】おすすめお薬手帳アプリ7選 ↗
OTC self-medication is a structural shift in Japan, not a one-off news event.
Drug-interaction data sources exist (Kegg) and a basic consumer app is buildable, but Japan's 薬機法 medical-device/medical-advice liability is high — recommending OTC could be construed as medical guidance, requiring disclaimers and careful scope to avoid regulatory exposure.Regulation of OTC Drugs in Japan - PMDA ↗